论文部分内容阅读
近年来,我国人口老龄化趋势加剧,在带来一系列社会问题的同时,却导致我国的医药卫生行业保持了持续十多年的高速增长。2010年1-7月医药制造业仍然保持较快增速,医药制造业1-7月累计实现总产值6431.60亿元,同比增长25.74%。而同期,A股市场中的医药板块也走出了凌厉走势,整体表现远强于大盘走势。在经历了如此长时间的上涨之后,医药板块是否还“有机可乘”?如果有,投资者又该如何把握?
In recent years, the trend of population aging in our country has intensified. While bringing about a series of social problems, the medical and hygienic industry in our country has maintained a rapid growth of more than 10 years. From January to July 2010, the pharmaceutical manufacturing industry still maintained rapid growth. The total output value of the pharmaceutical manufacturing industry from January to July reached 643.16 billion yuan, an increase of 25.74% over the same period of last year. The same period, the A-share market in the pharmaceutical sector has also come out of the sharp trend, the overall performance is far stronger than the market trend. After experiencing such a long time rise, is the medicine plate still “organic”? If so, how can investors hold it?